At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...
Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people 3 and often accompanied by cardiovascular complications. 4 People with Type 1 and Type 2 diabetes are 2 ...
How Much Can Abbott's Price Gain If FreeStyle Libre Gets 30% of The Blood Glucose Monitoring Market?
Abbott Labs’ (NYSE:ABT) stock price could gain over 10% if its FreeStyle Libre system captures a 30% share of the blood glucose monitoring market by 2020, according to our estimates. FreeStyle Libre ...
Powered by its Freestyle Libre glucose monitor and other medical devices, Abbott Laboratories posted a 2% increase in sales for its first quarter this year, topping $7.5 billion worldwide and ahead of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback